Unknown

Dataset Information

0

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.

ABSTRACT:

SUBMITTER: Xia S 

PROVIDER: S-EPMC8443232 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.

Xia ShengLi S   Zhang YunTao Y   Wang YanXia Y   Wang Hui H   Yang YunKai Y   Gao George Fu GF   Tan WenJie W   Wu GuiZhen G   Xu Miao M   Lou ZhiYong Z   Huang WeiJin W   Xu WenBo W   Huang BaoYing B   Wang Wei W   Zhang Wei W   Li Na N   Xie ZhiQiang Z   Zhu Xiujuan X   Ding Ling L   You WangYang W   Zhao YuXiu Y   Zhao Jun J   Huang LiLi L   Shi XueZhong X   Yang YongLi Y   Xu GuangXue G   Wang WenLing W   Liu PeiPei P   Ma Meng M   Qiao YuLing Y   Zhao SuHua S   Chai JingJing J   Li QinQin Q   Fu Hui H   Xu Ying Y   Zheng XiaoTong X   Guo WanShen W   Yang XiaoMing X  

The Lancet. Infectious diseases 20210915 2

<h4>Background</h4>Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 vaccine candidate BBIBP-CorV, we assessed the safety and immunogenicity of BBIBP-CorV in participants aged 3-17 years.<h4>Methods</h4>A randomised, double-blind, controlled, phase  ...[more]

Similar Datasets

Unknown Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
| S-EPMC7561304 | biostudies-literature
Unknown Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hypertensive and/or Diabetic People Aged over 60 Years: A Prospective Open-Label Study.
| S-EPMC9702925 | biostudies-literature
Unknown Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people.
| S-EPMC9239573 | biostudies-literature
Unknown Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
| S-EPMC7832443 | biostudies-literature
Unknown Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial.
| S-EPMC9695457 | biostudies-literature
Unknown Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
| S-EPMC10877779 | biostudies-literature
Unknown Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine.
| S-EPMC9719934 | biostudies-literature
Unknown Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
| S-EPMC7275151 | biostudies-literature
Unknown Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
| S-EPMC7825810 | biostudies-literature
Unknown Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
| S-EPMC9951829 | biostudies-literature